SYRE: Ascending Triangle detected on 17 Mar 2026

SYRE is forming an ascending triangle pattern on the heels of accelerating rheumatoid arthritis trial progress announced March 16, 2026, when recruitment for the RA sub-study of SKYWAY completed ahead of schedule. The pattern displays strong technical quality with a structure score of 15.0/15, breakout score of 13.0/13, and volume score of 12.0/12—an overall score of 92/98 with 77.41% win probability. Price is consolidating between support at $40.61 and resistance at $45.15, with current price at $44.07 (3.69% below 52-week high). Volume confirms conviction: current volume of 1.25M shares is 1.51x the 20-day average. The setup indicates institutional accumulation ahead of major catalyst events.

Spyre announced completion of recruitment for the RA sub-study of SKYWAY basket trial and acceleration of topline readout to Q3 2026, delivering a near-term de-risking catalyst. The company is pursuing six expected proof-of-concept readouts in 2026 across SKYLINE platform trial in UC and SKYWAY basket trial in RA, psoriatic arthritis, and axial spondylarthritis. All seven analysts covering the stock as of February assigned Buy ratings. Leerink reiterated an Outperform rating and $49 price target on March 16, 2026 following accelerated clinical timelines, while Mizuho initiated coverage with an Outperform rating and $53 price target. The company holds $756.5 million in cash and marketable securities as of December 31, 2025, funding operations into H2 2028. The timing aligns: stock rallied 7.3% in one week and 26.49% in one month leading into this announcement.

A successful breakout above $45.15 resistance would target $46.29 conservatively—roughly 51 basis points upside from current price. Historical ascending triangle patterns with win probability of 77.41% typically require volume above 1.2M shares to confirm breakout integrity; current 1.51x relative volume satisfies this requirement. The pattern invalidates decisively below the $40.61 support level, representing a 7.85% downside risk. The measured move suggests limited immediate upside, but the pattern quality score of 40/40 combined with clinical catalyst visibility through Q3 2026 indicates this consolidation precedes larger directional moves following data readout.

Merck's competing anti-TL1A therapy is already in Phase 3 development, placing pressure on Spyre to demonstrate superior clinical differentiation beyond dosing frequency—data disappointment could trigger sharp selloff. RSI at 65.74 approaches overbought territory (>70), signaling near-term momentum exhaustion despite bullish setup. Section 382 limitations may restrict $560 million in federal net operating loss carryforwards due to recent ownership changes. Stock-based compensation accounts for 18% of operating expenses at $38 million, suggesting ongoing shareholder dilution. The healthcare sector regime is bearish (regime score -0.17) and broader market is neutral (-0.18), creating macro headwinds. High beta of 1.24 amplifies volatility—a sharp market correction could gap support below $40.61. Q2 2026 SKYLINE monotherapy data readout arriving in 2-3 months introduces binary execution risk typical of early-stage biotech.